The A-share CRO concept sector declined, with Joinn Laboratories, Kairui Pharmaceutical, and Lingkang Pharmaceutical hitting their daily limit down, Biocytogen falling by more than 13%, and Prismed, Ruizhi Pharmaceutical, and Baihua Pharmaceutical all experiencing significant drops.